These results indicated TAM‐targeted delivery of siLTBR could abrogate TAM immunosuppressive capacity and remodel the proportion of tumor infiltrating immune cells by increasing CD8+ T cells as well as decreasing M2‐like TAMs and G‐MDSC, eventually resulting in tumor impedance. The gene discussed is CD8A; the disease is neoplasm.